• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PTEN 和 NM23 抑癌基因与 T1 期乳腺癌患者临床结局的相关性。

Correlation Between Onco-suppressors PTEN and NM23 and Clinical Outcome in Patients With T1 Breast Cancer.

机构信息

Pietro Valdoni Department of Surgery, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy;

Department of Radiological Sciences, Oncology and Pathology, Sapienza University, Rome, Italy.

出版信息

In Vivo. 2021 Jan-Feb;35(1):169-174. doi: 10.21873/invivo.12245.

DOI:10.21873/invivo.12245
PMID:33402463
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7880771/
Abstract

BACKGROUND

The aim of the present work was to evaluate the prognostic significance in patients with T1 breast cancer of tissue expression of the two oncosuppressors phosphatase and tensin homolog (PTEN) and non-metastatic clone 23 (NM23) as detected by immunohistochemistry.

MATERIALS AND METHODS

We prospectively analyzed 62 patients who underwent surgery for a T1 stage breast cancer. Expression of PTEN and NM23 was tested for correlation with clinical characteristics and clinical outcome.

RESULTS

Of the 62 patients considered for our study, 16 underwent mastectomy and 46 underwent conservative surgical treatment. The surgery was considered radical (R0) in all cases described. PTEN and NM23 expression was higher in patients with no lymph node metastases and no recurrent cancer at a mean follow-up of 36 months (range=6-48 months). This correlation was more evident when both PTNE and NM23 expression were highly expressed (p<0.0001).

CONCLUSION

Low or lack of PTEN and NM23 immunohistochemical expression in cancer tissue is a risk factor for lymph node involvement and recurrent disease. It may represent a valid prognostic factor in planning therapy in patients who had surgery for T1 breast cancer.

摘要

背景

本研究旨在通过免疫组化检测抑癌基因磷酸酶和张力蛋白同源物(PTEN)和非转移性克隆 23(NM23)的组织表达,评估其在 T1 期乳腺癌患者中的预后意义。

材料与方法

我们前瞻性分析了 62 例接受 T1 期乳腺癌手术的患者。检测了 PTEN 和 NM23 的表达,以评估其与临床特征和临床结局的相关性。

结果

在我们的研究中,62 例患者中有 16 例行乳房切除术,46 例行保留乳房的手术。所有病例的手术均为根治性(R0)。在平均随访 36 个月(6-48 个月)时,无淋巴结转移和无复发性癌症的患者中,PTEN 和 NM23 的表达更高。当 PTEN 和 NM23 的表达均高时,这种相关性更为明显(p<0.0001)。

结论

肿瘤组织中低表达或缺乏 PTEN 和 NM23 的免疫组化表达是淋巴结受累和疾病复发的危险因素。它可能是 T1 期乳腺癌患者手术治疗后计划治疗的一个有效的预后因素。

相似文献

1
Correlation Between Onco-suppressors PTEN and NM23 and Clinical Outcome in Patients With T1 Breast Cancer.PTEN 和 NM23 抑癌基因与 T1 期乳腺癌患者临床结局的相关性。
In Vivo. 2021 Jan-Feb;35(1):169-174. doi: 10.21873/invivo.12245.
2
nm23--relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts, and lymph node negative breast carcinoma patients.nm23——与乳腺癌细胞系、原发性人异种移植瘤及淋巴结阴性乳腺癌患者转移潜能的关系
Cancer. 1997 Mar 15;79(6):1158-65. doi: 10.1002/(sici)1097-0142(19970315)79:6<1158::aid-cncr14>3.0.co;2-z.
3
Co-downregulation of PTEN, KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer.非小细胞肺癌中PTEN、KAI-1和nm23-H1肿瘤/转移抑制蛋白的共同下调
Ann Diagn Pathol. 2004 Feb;8(1):6-16. doi: 10.1016/j.anndiagpath.2003.11.002.
4
[Expressions of survivin and nm23 and the relationship among the expressions and the axillary lymph node metastasis in breast cancer].[生存素和nm23的表达及其与乳腺癌腋窝淋巴结转移的关系]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005 Jun;30(3):312-4, 334.
5
[Expression and significance of PTEN and nm23 in the metastasis of gallbladder cancer].[PTEN和nm23在胆囊癌转移中的表达及意义]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005 Feb;30(1):46-8.
6
Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.区分乳腺癌的有利和不利预后标志物:E-钙黏蛋白的作用。
Cancer Res. 2000 Jan 15;60(2):298-304.
7
Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.CD44s、CD44v6和nm23 mRNA在人类癌症中的表达及意义
World J Gastroenterol. 2005 Nov 14;11(42):6601-6. doi: 10.3748/wjg.v11.i42.6601.
8
Expression of nm23-H1 gene and Sialyl Lewis X antigen in breast cancer.nm23-H1基因与唾液酸化路易斯X抗原在乳腺癌中的表达
Oncology. 1998 Jul-Aug;55(4):357-62. doi: 10.1159/000011878.
9
Nm23 gene product expression in invasive breast cancer--immunohistochemical analysis and clinicopathological correlation.Nm23基因产物在浸润性乳腺癌中的表达——免疫组织化学分析及临床病理相关性
Acta Oncol. 2002;41(4):355-61. doi: 10.1080/028418602760169406.
10
Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein.四种新型分子标志物的异常表达代表了乳腺癌中一种高度侵袭性的表型。对p53、nm23、erbB-2和组织蛋白酶D蛋白进行免疫组织化学检测。
J Surg Oncol. 1997 May;65(1):22-7. doi: 10.1002/(sici)1096-9098(199705)65:1<22::aid-jso5>3.0.co;2-q.

引用本文的文献

1
The effects of the tumor suppressor gene on the proliferation and apoptosis of breast cancer cells via AKT phosphorylation.肿瘤抑制基因通过AKT磷酸化对乳腺癌细胞增殖和凋亡的影响。
Transl Cancer Res. 2023 Jul 31;12(7):1863-1872. doi: 10.21037/tcr-23-826. Epub 2023 Jul 28.
2
Sentinel Lymph Node Detection in Breast Cancer: An Innovative Technique.乳腺癌前哨淋巴结检测:一种创新技术。
Diagnostics (Basel). 2023 Jun 12;13(12):2030. doi: 10.3390/diagnostics13122030.

本文引用的文献

1
[Breast cancer epidemiology].[乳腺癌流行病学]
Presse Med. 2019 Oct;48(10):1076-1084. doi: 10.1016/j.lpm.2019.09.022. Epub 2019 Nov 6.
2
The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer.美国联合委员会癌症第 8 版预后分期包括 Oncotype DX®复发评分:对早期乳腺癌分期的影响。
Pathobiology. 2019;86(2-3):77-82. doi: 10.1159/000493363. Epub 2018 Oct 22.
3
Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.乳腺癌中PTEN表达缺失:与临床病理特征及预后的关联
Oncotarget. 2017 May 9;8(19):32043-32054. doi: 10.18632/oncotarget.16761.
4
[Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and 
the correlation among them].[PTEN、p53和EGFR在乳腺癌分子亚型中的表达及其相关性]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2015 Sep;40(9):973-8. doi: 10.11817/j.issn.1672-7347.2015.09.005.
5
Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.非小细胞肺癌、神经胶质瘤和乳腺癌样本中p53、PTEN和p16的单个及多个改变的比较分析。
Biomed Pharmacother. 2014 Jun;68(5):521-6. doi: 10.1016/j.biopha.2014.03.014. Epub 2014 Mar 28.
6
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.评估 PIK3CA 突变和 PTEN 缺失与曲妥珠单抗治疗转移性乳腺癌疗效的关系。
Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19.
7
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.原发性和转移性乳腺癌中的 PI3K 通路突变和 PTEN 水平。
Mol Cancer Ther. 2011 Jun;10(6):1093-101. doi: 10.1158/1535-7163.MCT-10-1089. Epub 2011 Apr 13.
8
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.乳腺癌中 PI3K 通路的激活与基底样表型和癌症特异性死亡率相关。
Int J Cancer. 2010 Mar 1;126(5):1121-31. doi: 10.1002/ijc.24831.
9
Expression of nm23 in the spectrum of pre-invasive, invasive and metastatic breast lesions.nm23 在乳腺病变的癌前、浸润和转移谱中的表达。
Diagn Pathol. 2008 May 30;3:23. doi: 10.1186/1746-1596-3-23.
10
PTEN and VEGF: possible predictors for sentinel lymph node micro-metastasis in breast cancer.PTEN与血管内皮生长因子:乳腺癌前哨淋巴结微转移的潜在预测指标
Biomed Pharmacother. 2007 Oct;61(9):558-61. doi: 10.1016/j.biopha.2007.08.015. Epub 2007 Sep 17.